glp-1 drugs and fatty liver Full article: receptor agonists in the treatment of diabetic non–alcoholic steatohepatitis patients Pharmacological treatment of steatotic liver

Individuals with obesity, both with and without T2DM, show increased risks for gastrointestinal bleeding when treated with GLP-1R agonists combined with aspirin [140]

doi: 10.1056/NEJMoa1509225 251 HolmanRRBethelMAMentzRJThompsonVPLokhnyginaYBuseJBet al

At the 12mg dose, that figure jumped to 20.9%

Strategies on how to manage these and other side effects are described in more detail here: Figure 3 of this article and Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists

6.8% in the triple therapy and conventional therapy arms respectively ( p = 0.0006)

PMID: 38041774